Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of carfilzomib + cyclophosphamide + dexamethasone in newly diagnosed multiple myeloma
2010-021111-17Phase 2Completed
- Sponsor
- HOVON
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by HOVON. Primary endpoints: Toxicity and Partial remission rate. Started Apr 2011; status: completed.
02
Drugs
carfilzomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-021111-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021111-17.